GlassScriptPhysician profile
Walter W Chien
NPI 1386615631
$27,709.16
in general payments reported to CMS, 2019-2025
22 companies · $2,932 in 2025
The $2,932 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,225 · 2020: $1,803 · 2021: $2,809 · 2022: $13K · 2023: $1,947 · 2024: $93.50 · 2025: $2,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,834 · Food and Beverage: $1,493 · Travel and Lodging: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,834.00 |
| Food and Beverage | $1,492.81 |
| Travel and Lodging | $646.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16,450.26 | 2021-2025 | Selectsecure, Micra, Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $5,195.58 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $3,085.34 | 2022-2025 | |
| Boston Scientific Corporation | $1,101.81 | 2019-2023 | Watchman Access System |
| Abbott Laboratories | $412.91 | 2019-2024 | Amplatzer Talisman, Ensite, Gallant |
| Novo Nordisk INC | $338.32 | 2019-2022 | |
| Amgen INC. | $196.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $135.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.32 | 2019-2022 | |
| Pfizer INC. | $122.09 | 2019-2023 | |
| Amarin Pharma, INC. | $120.43 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.74 | 2021 | |
| Atricure, INC. | $75.25 | 2019 | |
| Csl Behring | $45.15 | 2020 | |
| Sanofi-Aventis U.S. LLC | $39.18 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $38.05 | 2021 | |
| Lilly USA, LLC | $36.04 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $26.81 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.60 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $22.45 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.30 | 2019 | |
| Abbvie INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Chien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.